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Substantial evidence supports a critical role for the activation of the Raf-1/MEK/mitogen-activated protein
kinase pathway in oncogenic Ras-mediated transformation. For example, dominant negative mutants of Raf-1,
MEK, and mitogen-activated protein kinase all inhibit Ras transformation. Furthermore, the observation that
plasma membrane-localized Raf-1 exhibits the same transforming potency as oncogenic Ras suggests that
Raf-1 activation alone is sufficient to mediate full Ras transforming activity. However, the recent identification
of other candidate Ras effectors (e.g., RalGDS and phosphatidylinositol-3 kinase) suggests that activation of
other downstream effector-mediated signaling pathways may also mediate Ras transforming activity. In sup-
port of this, two H-Ras effector domain mutants, H-Ras(12V, 37G) and H-Ras(12V, 40C), which are defective
for Raf binding and activation, induced potent tumorigenic transformation of some strains of NIH 3T3 fibro-
blasts. These Raf-binding defective mutants of H-Ras induced a transformed morphology that was indistin-
guishable from that induced by activated members of Rho family proteins. Furthermore, the transforming
activities of both of these mutants were synergistically enhanced by activated Raf-1 and inhibited by the domi-
nant negative RhoA(19N) mutant, indicating that Ras may cause transformation that occurs via coordinate
activation of Raf-dependent and -independent pathways that involves Rho family proteins. Finally, cotrans-
fection of H-Ras(12V, 37G) and H-Ras(12V, 40C) resulted in synergistic cooperation of their focus-forming
activities, indicating that Ras activates at least two Raf-independent, Ras effector-mediated signaling events.
Ras proteins act as molecular switches that cycle between
active GTP- and inactive GDP-bound forms (reviewed in ref-
erences 6 and 9) and function as essential components of signal
transduction pathways that regulate cell growth and differen-
tiation (reviewed in references 21, 36, and 51). Upon activation
by ligand-stimulated receptors, activated Ras proteins transmit
their signals to a cascade of serine/threonine kinases (reviewed
in references 59, 64, 68, and 86). Activated Ras complexes with
and promotes activation of the Raf-1 serine/threonine kinase
(50, 76, 78, 79, 87). Raf-1 in turn activates mitogen-activated
protein kinase (MAPK) kinases (MEK1 and MEK2), which in
turn activate p42 and p44 MAPKs/extracellular signal-regu-
lated kinases (ERKs) (16, 34, 41, 42, 61, 88). Activated MAPKs
then translocate into the nucleus, where they phosphorylate
and activate nuclear transcription factors such as Elk-1 (30),
resulting in immediate-early gene induction (reviewed in ref-
erences 31 and 47).
The critical involvement of the Raf/MEK/MAPK cascade in
mediating Ras transformation is supported by a number of
experimental observations. First, kinase-deficient mutants of
Raf-1, MEKs, and MAPKs have been shown to block Ras-
mediated signaling events and transformation (14, 37, 39, 58,
67, 81). Second, constitutively activated mutants of Raf-1 ex-
hibit strong transforming activities in rodent fibroblast trans-
formation assays (7, 73). For example, the potent transforming
activity of the plasma membrane-targeted Raf-1 has prompted
suggestions that Ras may function primarily to promote the
translocation of Raf-1 from the cytosol to the plasma mem-
brane, where subsequent Ras-independent events trigger Raf-1
kinase activation (43, 74). Consistent with this possibility, con-
stitutively activated Raf-1 is sufficient to overcome the loss of
Ras function caused by the Ras(17N) dominant negative or the
Y13-259 anti-Ras neutralizing antibody (24, 71). Third, consti-
tutively activated MEKs can cause tumorigenic transformation
of NIH 3T3 cells (3, 45). Finally, genetic studies with Drosoph-
ila melanogaster and Caenorhabditis elegans have shown that
gain-of-function mutations in Raf, MEK, or MAPK homologs
can overcome defects in Ras (18, 28, 44, 75). Taken together,
these observations support the possibility that Ras-mediated
activation of the Raf/MEK/MAPK pathway is both necessary
and sufficient for oncogenic Ras transformation.
Despite the evidence that Raf-1 is a critical downstream
effector of Ras function, there is increasing evidence that Ras
may mediate its actions through the activation of multiple
downstream effector-mediated pathways (23). For example,
the existence of Raf-independent Ras signaling pathways is
suggested by the expanding roster of candidate Ras effectors
that have been identified (27, 33, 38, 58, 65, 66, 72, 76–78). Like
Raf-1, these functionally diverse proteins show preferential
binding to the active GTP-bound form of Ras, and this inter-
action requires an intact Ras effector domain (amino acids 32
to 40). For example, although the two Ras GTPase-activating
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proteins (GAPs) clearly function as negative regulators of Ras,
there is also evidence that they serve a dual role and may also
be important downstream targets of Ras (reviewed in refer-
ences 6 and 25). Yeast two-hybrid studies have identified two
guanine nucleotide exchange factors (GEFs) for Ras-related
proteins RalA and RalB (RalGDS and RGL/Rsb3), as well as
additional novel proteins, as candidate Ras effectors (33, 38,
72, 77, 78). Phosphatidylinositol-3-OH kinase has also been
shown to complex with Ras and to exhibit the properties of a
Ras effector (65). Finally, additional candidate Ras effectors
include mammalian Rin-1, MEK kinase 1, and AF6/Rsb1, Sac-
charomyces cerevisiae adenylyl cyclase (CYR1), and the Schizo-
saccharomyces pombe byr2 and scd1 proteins (10, 27, 66, 76–
78). AF6 has been previously defined as part of a fusion
protein coded for by a hybrid gene caused by a translocation in
acute lymphocytic leukemia and may be a critical Ras effector
in hematopoietic systems (40). To date, the precise role of
these candidate effectors in mediating Ras downstream signal
transduction and transformation remains to be established.
Additional evidence for the involvement of multiple down-
stream events is provided by observations from genetic, bio-
chemical, and biological studies that suggest that Ras acts
through members of the Rho family of Ras-related proteins
(RhoA, RhoB, RhoC, RhoG, Rac1, Rac2, CDC42, and TC10).
First, genetic studies of fission yeast S. pombe Ras (ras1) func-
tion have identified two distinct ras1 effector-mediated activi-
ties (10). One involves ras1 interaction with byr2 (a MEK
kinase homolog), and the other involves ras1 interaction with
scd1 (a putative Rho GEF). scd1 in turn may regulate the
function of the cdc42sp Rho family protein. Second, Swiss 3T3
mouse fibroblast microinjection studies showed that the onco-
genic Ras-induced alterations of actin cytoskeletal organiza-
tion (5) may be mediated via activation of two Rho family
proteins, Rac1 and RhoA (62, 63). Third, the inhibition of onco-
genic Ras transformation by dominant negative mutants of
three Rho family proteins (RhoA, RhoB, and Rac1) demon-
strated that full Ras transformation was dependent on Rho
protein function (37, 56, 58). In contrast, interfering Rac1 or
RhoA mutants weakly blocked Raf transforming activity (37,
58). Finally, the synergistic transforming activity seen after
activated Raf-1 is coexpressed with constitutively activated
RhoA or Rac1 suggests that coordinate activation of the Raf/
MEK/MAPK pathway and Rho proteins may be required for
full Ras transformation (37, 58). How Rho protein function
may contribute to Ras transformation is presently not known.
Rho family proteins have been shown to be regulators of actin
cytoskeletal organization (reviewed in references 11, 19, and
26) and may also trigger changes in gene expression by mod-
ulating the activities of various transcription factors (13, 32, 49,
53).
Clear genetic evidence that Ras mediates transformation by
activating Raf-dependent and Raf-independent pathways was
demonstrated by our discovery of H-Ras effector domain mu-
tants that separate the abilities of H-Ras to interact with dif-
ferent downstream targets (83). Mutations in the Ras effector
domain (residues 32 to 40) can impair Ras transforming activ-
ity and interaction with effector proteins without causing alter-
ations in intrinsic GDP and GTP regulation (reviewed in ref-
erence 48). Although one of these mutants [H-Ras(12V, 37G)]
failed to bind Raf-1, it retained the ability to synergistically
enhance the transforming activity of another H-Ras effector
domain mutant [H-Ras(12V, 35S)] which retained full-length
Raf-1 binding activity (1, 20, 70, 83). This observation sug-
gested that H-Ras(12V, 37G) retained the ability to trigger a
Raf-independent signaling pathway that was required for full
Ras transformation. The identity of this Raf-independent sig-
naling pathway(s) has not been established.
In the present study, we have analyzed the role of Raf-
independent signaling pathways in growth transformation by
using two H-Ras effector domain mutants, H-Ras(12V, 37G)
and H-Ras(12V, 40C), that failed to bind full-length Raf-1 but
that could bind to other candidate effectors in yeast two-hybrid
analyses (83). We observed that both mutants were impaired in
their abilities to stimulate the Raf/MAPK/Elk pathway, and yet
they retained the ability to cause a potent tumorigenic trans-
formation of some cell strains. However, the transformed phe-
notype induced by the Raf-binding defective mutants in these
strains was distinct from that caused by oncogenic Ras and
instead was indistinguishable from the transformed focus and
morphology seen with Rho- or Rho GEF-transformed NIH
3T3 cells (35, 37, 56). Finally, H-Ras(12V, 37G) and H-Ras
(12V, 40C) cooperated and showed synergistic induction of
transformed foci, suggesting their abilities to trigger at least
two distinct, Raf-independent pathways that promote Ras
transformation. Taken together, our observations indicate that
coordinate activation of Raf-dependent and Raf-independent
pathways by oncogenic Ras may be required to mediate full
Ras-induced transforming activity. Furthermore, the activation
of the Raf-independent pathway(s) is sufficient to cause cellu-
lar transformation and requires the participation of Rho family
proteins.
MATERIALS AND METHODS
Molecular constructs. All ras expression constructs encode mutant versions of
the transforming human H-Ras(12V) protein. pHP5-H-ras(12V), pHP5-H-ras
(12V,35S), pHP5-H-ras(12V,37G), and pHP5-H-ras(12V,40C) are expressed as
LexA-binding domain fusions, and pGAD-raf1 is expressed as a GAL4 activation
domain fusion and has been described previously. The pDCR-ras(12V), pDCR-
ras(12V,35S), pDCR-ras(12V,37G), and pDCR-ras(12V,40C) mammalian con-
structs encode effector domain mutants of H-Ras(12V) in which expression is
under the control of the cytomegalovirus promoter (83). pZIP-raf(340D) and
pCEP4-rafBXB encode mutants of Raf-1 which contain either a single amino
acid substitution (Y-3403D) (22) or an N-terminal truncation of the Ras-bind-
ing domain (80), respectively, and have been described previously (37, 83). pZIP-
rhoA(63L) encodes a transforming mutant human RhoA protein which contains
a substitution analogous to the Q-613L mutation which activates Ras trans-
forming activity (17, 37). pGEX-mek1(WT), pGEX-mek1(KR), pGEX-erk1
(KR), and pGEX-c-jun(WT) were used as described previously to generate sub-
strates for the kinase assays (2, 82).
Yeast two-hybrid assay. The yeast strains and media for performance of the
yeast two-hybrid binding analyses were described previously (48, 77). Like H-ras
(37G), H-ras(40C) was isolated from a PCR-derived randomly mutagenized
H-ras library which was fused to the GAL4 DNA-binding domain and found to
show no interaction with Raf-1 fused to the GAL4 activation domain. Additional
Ras binding partners were expressed as GAL4 activation domain fusions con-
taining the Ras binding sequences from RalGDS, AF6 (residues 1 to 180), cyr1,
and byr2 (77). AF6 was previously described in a single example as a fusion
partner for ALL-1 in acute lymphoblastic leukemias (55). Interactions between
Ras–GAL4 DNA-binding domain fusions and Ras binding partner-GAL4 acti-
vation domain fusions were performed in S. cerevisiae reporter strain YPB2 and
assayed for b-galactosidase activity on filters.
Cell culture and transformation assays. NIH 3T3(CSHL) and NIH 3T3(UNC)
are two independent strains of NIH 3T3 fibroblasts that were isolated for their
flat shapes and low rates of spontaneous transformation and have been used
previously for Ras transformation studies (12, 83). DNA transfections were done
by the calcium phosphate precipitation technique as previously described (12,
85). Ten nanograms of pDCR-rasH(12V), 100 ng of the effector domain mutants,
100 ng of pCEP4-rafBXB, 1 mg of pZIP-raf(340D), and 1 mg of pZIP-rhoA(63L)
were used in each dish for transformation studies with NIH 3T3(UNC) cells.
Transfected cells were maintained in growth medium, and the appearance of
transformed foci was quantitated after 14 to 16 days. To establish NIH 3T3
(UNC) cell lines expressing each protein, the transfected cells were selected in
growth medium containing 400 mg of Geneticin (G418; GIBCO/BRL) per ml.
NIH 3T3(UNC) cells expressing oncogenic and various effector domain mutants
were examined, and their growth rates and saturation densities on plastic, their
abilities to proliferate in low serum (1%) or soft agar (0.3%), and their abilities
to form tumors after being inoculated subcutaneously into athymic nude mice
(105 cells per site) were compared by procedures that we have described previ-
ously (12).
The ability of Raf-1 and RhoA mutant proteins to modulate the focus-forming
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activity of the effector domain mutants was determined by cotransfection focus-
formation assays. Cultures were transfected with oncogenic Ras or effector
domain mutants alone or together with plasmid DNA expression vectors encod-
ing activated Raf-1 (340D or BXB) or RhoA(63L) proteins. The appearance of
transformed foci was quantitated after 14 to 16 days. Data gathered were rep-
resentative of two or more independent determinations, with each determination
representing the number of foci seen in four dishes.
Protein expression. Protein expression from the exogenously introduced wild-
type and mutant H-ras cDNA sequences in stably transfected NIH 3T3(UNC)
cells was determined by Western blot (immunoblot) analyses of G418-selected
cell lysates. Ras expression was determined with the mouse 146-3E4 anti-H-Ras-
specific monoclonal antibody (Quality Biotech) (15). Detection of antibody was
done by enhanced chemiluminescence (Amersham).
Transient transfection luciferase assays. To compare the abilities of the dif-
ferent effector domain mutants to induce transcriptional activation of the Ras-
responsive Elk-1 transcription factor, NIH 3T3(UNC) cells were transiently
cotransfected with 250 ng of plasmid DNA encoding mutant Ras together with
2.5 mg of the Gal-luc and 250 ng of the Gal-elk fusion constructs (provided by
M. Karin and R. Treisman, respectively) by procedures described previously
(29). Forty-eight hours after transfection, cell lysates were prepared in 200 ml of
luciferase cell lysis buffer. Fifty microliters of the lysate was then assayed in a
luminometer with 100 ml of ATP and luciferin reagent. The fold luciferase
activity was then calculated by dividing the luciferase activity of the Ras mutants
by the activity of the sample containing the vector alone as described previously.
The data represent two experiments performed in duplicate.
In vitro Raf kinase and MAPK assays. NIH 3T3(UNC) cells expressing on-
cogenic Ras and various effector domain mutants were lysed in a modified RIPA
buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 5 mM
EDTA, 50 mM HEPES [N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid]
[pH 7.5], 1 mM sodium vanadate, 50 mM NaF, and phosphatase inhibitors).
Raf-1 or MAPK/ERK was then immunoprecipitated with anti-Raf-1 (C-12) or
anti-ERK1 (C-16) rabbit polyclonal antibody (Santa Cruz Biotech), respectively.
The Raf-1 immunocomplex kinase assay was then carried out in a coupled assay.
Raf was incubated with 2 to 5 mg of wild-type MEK1 for 15 min and then with
2 to 5 mg of the kinase-deficient mutant of MAPK for 15 min in a kinase assay
in the presence of a solution containing 25 mM HEPES (pH 7.5), 25 mM
Mg2Cl2, 2 mM dithiothreitol, 0.1 M Na3VO4, phosphatase inhibitors, and [g-32P]
ATP at room temperature. The MAPK immunocomplex assay was carried out by
incubating the immunoprecipitated MAPK with 12 mg of myelin basic protein in
a kinase assay for 30 min at room temperature. The reactions were then stopped
with 23 sodium dodecyl sulfate (SDS) sample buffer. The proteins were then
separated on an SDS–15% polyacrylamide gel and visualized by autoradiography
(2).
In vitro JNK activation assay. NIH 3T3(UNC) cells stably expressing each
effector domain mutant were lysed in modified RIPA buffer. Lysate containing
approximately 30 mg proteins was incubated with 1 to 5 mg of GST-c-Jun(1-79)
substrate (provided by M. Karin) in a kinase assay as described above. Proteins
were then separated by SDS-polyacrylamide gel electrophoresis, and phosphor-
ylation of the substrate was observed following autoradiography (82). Transient
Jun kinase (JNK) assays were carried out by transfection of COS-7 cells with 1 mg
of each effector domain mutant along with 1 mg of pCMV-(M2)JNK with Lipo-
fectamine, according to the manufacturer’s procedures (GIBCO/BRL). The cells
were then lysed on day 3 with modified RIPA buffer. JNK was immunoprecipi-
tated with the M2 Flag antibody (IBI) and used in a kinase assay as described
above in the presence of 2 of GST-c-Jun(1-79).
Immunofluorescence analyses. For visualization of stress fibers and focal ad-
hesion components, cells were plated on coverslips in growth medium (35). After
16 to 24 h, the cells were fixed in 3.7% formaldehyde in phosphate-buffered
saline for 7 min, washed in Tris-buffered saline (150 mM NaCl, 50 mM Tris-HCl
[pH 7.6], 0.1% sodium azide), and permeabilized with 0.5% Triton X-100 in
Tris-buffered saline for 6 min. Double labeling was performed as described
previously (35). Briefly, polymerized actin was stained with either 600 mU of
tetramethyl rhodamine isothiocyanate-phalloidin per ml or 5 U of fluorescein
isothiocyanate-phalloidin (Molecular Probes, Inc., Eugene, Oreg.) per ml. The
focal adhesion protein, vinculin, was treated with 7f9 antivinculin monoclonal
antibody and then with fluorescein isothiocyanate-conjugated goat anti-mouse
immunoglobulin G (Jackson ImmunoResearch Laboratories, Inc., West Grove,
Pa.) or tetramethyl rhodamine isothiocyanate-conjugated goat anti-mouse im-
munoglobulin G (Chemicon International, Inc., Temecula, Calif.).
RESULTS
The Raf-binding defective mutants of H-Ras are defective in
activation of the Raf/MAPK/Elk pathway.We recently showed
that the H-Ras(12V, 37G) mutant could complement the
transforming activity of the H-Ras(12V, 35S) mutant, indicat-
ing that Raf-independent pathways activated by Ras can con-
tribute to transformation (83). We sought to determine if ac-
tivation of Raf-independent pathways could in themselves lead
to tumorigenic transformation. However, the H-Ras(12V, 37G)
mutant had no focus-forming activity in the NIH 3T3(CSHL)
strain (83). We have observed that different isolates of NIH
3T3 cells differ with respect to their abilities to form foci in
response to activated Rho family members. Whereas the NIH
3T3(UNC) strain is responsive to transformation by constitu-
tively activated mutants of RhoA and Rac1 (37), the NIH 3T3
(CSHL) strain is not (83a). Therefore, we sought to character-
ize the transforming activity of the H-Ras(12V, 37G) mutant in
NIH 3T3(UNC) and other cell lines. For these purposes, we
decided to test another effector loop mutant of H-Ras, H-Ras
(12V, 40C), which also failed to bind to full-length Raf-1 in the
two-hybrid system (Fig. 1A) but which retained the ability to
interact with another candidate target, AF6, which has been
described previously (Table 1 shows the matrix of mutant H-
Ras interactions with candidate effectors) (77).
First, we determined if H-Ras(12V, 37G) and H-Ras(12V,
40C) were impaired in their abilities to upregulate the Raf/
MAPK pathway after being expressed in cells of the NIH 3T3
(UNC) strain. These cells were stably transfected with H-Ras
(12V) or each of the effector domain mutants. Multiple G418-
resistant colonies (.100) were pooled, and Western blot anal-
ysis showed that they expressed comparable levels of mutant
H-Ras protein (Fig. 1B). Whereas cells expressing H-Ras(12V)
and H-Ras(12V, 35S) exhibited elevated Raf-1 kinase activities
(20- and 6-fold, respectively) after being assessed in a Raf-1
immunocomplex-coupled in vitro kinase assay, cells expressing
H-Ras(12V, 37G) or H-Ras(12V, 40C) showed the same low
Raf-1 kinase activity seen in untransfected NIH 3T3(UNC)
cells (Fig. 1C). These observations are consistent with the yeast
two-hybrid binding results and demonstrated that both H-Ras
(12V, 37G) and H-Ras(12V, 40C) were impaired in their abil-
ities to activate Raf-1 kinase in mammalian cells.
Consistent with their impaired abilities to upregulate Raf-1
kinase activity, cells expressing H-Ras(12V, 37G) and H-Ras
(12V, 40C) showed no significant increase in p42 and p44
MAPK activities, as measured by their abilities to phosphory-
late myelin basic protein in vitro (Fig. 1D). In contrast, both
H-Ras(12V)- and H-Ras(12V, 35S)-expressing cells showed
elevated MAPKs (7- and 3-fold elevations, respectively). Fi-
nally, we analyzed the ability of these effector domain mutants
to activate the Elk-1 transcription factor in transiently trans-
fected NIH 3T3(UNC) cells. Elk-1 has been shown to be a
substrate for MAPK phosphorylation, and Elk-1 transcrip-
tional activity can be stimulated by oncogenic Ras activation of
the Raf/MEK/MAPK pathway (46, 60). We found that H-Ras
(12V, 35S) but not H-Ras(12V, 37G) or H-Ras(12V, 40C),
retained the ability to stimulate transcriptional activity of Elk-1
(Fig. 1E). Thus, both Raf-binding defective mutants were im-
paired in their abilities to activate components downstream of
Ras and Raf-1.
Ras mutants which are defective in activation of the Raf/
MAPK pathway cause tumorigenic transformation. We next
determined whether H-Ras(12V, 37G) or H-Ras(12V, 40C)
retained the ability to cause transformation of NIH 3T3(UNC).
In contrast to the NIH/3T3(CSHL) strain, the NIH 3T3(UNC)
strain was able to have foci induced by these mutants, although
the frequency was greatly attenuated (60- and 110-fold reduc-
tions, respectively) compared with the focus-forming activity of
H-Ras(12V) (4 3 103 to 8 3 103 transformed foci per mg of
transfected DNA) (Fig. 2). Similarly, we observed that these
Ras effector domain mutants also caused focus formation in
Rat-1 fibroblasts and RIE-1 rat intestinal epithelial cells (52a).
We next characterized the growth properties of NIH 3T3
(UNC) cells stably expressing each mutant Ras protein. For
these analyses, we used both mass populations of newly trans-
fected, G418-resistant cells (pooled from more than 100 drug-
VOL. 16, 1996 Rho AND Ras-MEDIATED TRANSFORMATION 3925
 o
n
 April 12, 2012 by M
AIN LIBRARY
http://m
cb.asm
.org/
D
ow
nloaded from
 
resistant colonies) as well as clonal populations which were
established from individual G418-resistant transformed colo-
nies. Mass populations of cells expressing H-Ras(12V, 37G) or
H-Ras(12V, 40C) showed enhanced growth properties and
higher saturation densities compared with untransformed NIH
3T3(UNC) cells, comparable in magnitude to those observed
for cells expressing H-Ras(12V) or H-Ras(12V, 35S) (Fig. 3).
Additionally, mass populations of NIH 3T3(UNC) cells ex-
pressing H-Ras(12V, 37G) and H-Ras(12V, 40C) also prolif-
erated in growth medium supplemented with low serum (1%)
and formed colonies in soft agar (Table 2). Most importantly,
cells expressing either Raf-binding defective mutant caused
rapid tumor formation after being inoculated into nude mice
(Table 2). Clonal populations derived from individual G418-
resistant, transformed colonies that possessed comparable lev-
els of protein expression also exhibited essentially the same
enhanced growth properties in all of these growth assays (data
not shown). These results clearly demonstrate that oncogenic
Ras can cause potent tumorigenic transformation by activation
of a Raf/MAPK-independent pathway(s). Furthermore, the po-
tent growth transformation induced by H-Ras(12V, 37G) or
H-Ras(12V, 40C) contrasts dramatically with their weak focus-
forming activities and suggests that focus-forming potential is
not an accurate measure of their growth transforming activi-
ties.
H-Ras(12V, 37G) and H-Ras(12V, 40C) cause morphologi-
cal transformation indistinguishable from that induced by
constitutively activated Rho proteins. H-Ras(12V, 37G) and
H-Ras(12V, 40C) caused the appearance of transformed foci
which were clearly distinct from the transformed foci induced
by oncogenic H-Ras(12V) mutants (Fig. 4A and B). Whereas
H-Ras(12V) or H-Ras(61L), as well as transforming mutants
of Raf-1 (data not shown), caused the appearance of large,
swirled foci that contained highly refractile and spindle-shaped
cells, H-Ras(12V, 37G) and H-Ras(12V, 40C) caused the ap-
pearance of circle-shaped foci that contained densely packed
nonrefractile cells (Fig. 4A). The appearance of these foci was
indistinguishable from that of the transformed foci caused by
constitutively activated mutants of Rho family proteins (RhoA,
RhoB, and Rac1) (Fig. 4A) (37, 56) or Rho GEFs (e.g., Dbl
and Vav) (35). Consistent with its retention of a Raf/MAPK
signaling activity, H-Ras(12V, 35S) also induced Ras- or Raf-
like transformed foci (Fig. 4A). Finally, the cellular morphol-
ogy of isolated NIH 3T3(UNC) cells stably expressing H-Ras
(12V, 37G) or H-Ras(12V, 40C) was also very distinct from the
highly refractile, spindle-shaped morphology of H-Ras(12V)-
or H-Ras(12V, 35S)-transformed cells. Instead, their cellular
morphologies were essentially the same as those of cells trans-
formed by activated RhoA(63L) (Fig. 4B) (35). Cells express-
ing either Raf-binding defective H-Ras mutant or RhoA(63L)
retained the nonrefractile appearance and well adherent na-
ture of untransformed NIH 3T3 cells.
Because the two Raf-binding defective mutants caused
FIG. 1. H-Ras(12V, 35S), but not H-Ras(12V, 37G) or H-Ras(12V, 40C),
interacts with and causes activation of Raf-1 and MAPKs and Elk-1 transcrip-
tion. (A) Yeast two-hybrid analysis was done to determine if the different Ras
effector domain mutants are impaired in their abilities to bind full-length Raf-1.
b-Galactosidase activity was determined by filter assay. Yeast patches containing
interacting protein pairs are dark, owing to b-galactosidase activity and X-Gal
(5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside) cleavage product. Yeast
patches containing noninteracting protein pairs remain white, owing to the ab-
sence of detectable b-galactosidase activity. (B) Western blot analysis with the
146 anti-H-Ras-specific monoclonal antibody was done to quantitate the level of
mutant Ras expression in each NIH 3T3(UNC) cell line transfected with the
indicated expression construct. The data shown are representative of three in-
dependent Western blot analyses with lysates generated from equivalent num-
bers of cells expressing each mutant protein. (C) In vitro Raf kinase assays were
done on immunoprecipitated Raf-1 from lysates of equivalent cell numbers of
NIH 3T3(UNC) cells stably expressing each mutant H-Ras protein with a Raf-
immunocomplex-coupled kinase assay. Raf-1 was immunoprecipitated with the
C-12 Raf-1 polyclonal antibody (Santa Cruz Biotech) and then incubated with
wild-type MEK1, and this incubation was followed by incubation with kinase-
deficient p42 MAPK/ERK2(KR) in the presence of [g-32P]ATP (2). Numbers
indicate fold elevation relative to vector-transfected cells. The data shown are
representative of four independent assays. (D) The level of activated MAPKs in
lysates from NIH 3T3(UNC) cells stably expressing each mutant H-Ras protein
was determined by an in vitro immunocomplex kinase assay with the C-16
anti-ERK1 (Santa Cruz Biotech) rabbit polyclonal antibody and by a subsequent
incubation with myelin basic protein as a substrate in presence of g-32P (2).
Numbers indicate fold elevation relative to vector-transfected cells. The data
shown are representative of four independent assays. (E) NIH 3T3(UNC) cells
were transiently transfected with expression constructs encoding each H-Ras
mutant (250 ng) along with 2.5 mg of Gal-luc and 250 ng of Gal-elk plasmid
DNAs to determine the activation of Elk-1 transcriptional activity in a luciferase
assay with 100 ml of ATP and luciferin reagent in a luminometer (29). The data
shown are the fold activation for duplicate transfections and are representative
of three independent assays.
TABLE 1. Interaction between Ras effector domain mutants
and Ras binding partnersa
Mutant protein Raf-1 byr2 AF6/Rsb1b RalGDS RGL/Rsb3b cyr1
H-Ras(12V) 1 1 1 1 1 1
H-Ras(12V, 35S) 1 2 6 1 1 2
H-Ras(12V, 37G) 2 1 1 1 1 1
H-Ras(12V, 40C) 2 2 1 2 2 2
a 1, strong interaction; 2, no interaction; 6, weak interaction.
b Isolated by yeast two-hybrid library screening as described previously (77).
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transformed foci and cellular morphologies that were similar
to those caused by transforming mutants of Rho proteins or
Rho GEFs, we next analyzed the cytoskeletal organization of
cells expressing these mutant proteins. We previously reported
that whereas oncogenic Ras-transformed cells exhibit a loss of
actin stress fibers and focal adhesions, RhoA- and Dbl-trans-
formed cells retain well organized actin stress fibers and abun-
dant focal adhesions (35). Indirect immunofluorescence anal-
ysis showed that like H-Ras(12V)-transformed cells, H-Ras
(12V, 35S)-transformed cells exhibit disrupted actin stress fi-
bers and reduced focal adhesions (Fig. 4C). In contrast, both
H-Ras(12V, 37G)- and H-Ras(12V, 40C)-transformed cells
retain organized actin stress fibers and abundant focal adhe-
sions characteristic of untransformed NIH 3T3(UNC) cells
(35). Thus, like constitutively activated mutants of RhoA,
Rac1, Dbl, and Vav, H-Ras(12V, 37G) and H-Ras(12V, 40C)
cause tumorigenic transformation without causing a concomi-
tant loss of actin cytoskeletal organization.
H-Ras(12V, 37G) and H-Ras(12V, 40C) activate JNK, as do
members of the Rho family of proteins. Recent studies dem-
onstrated that two members of the Rho family (Rac1 and
CDC42Hs), as well as Rho GEFs (e.g., Dbl), caused activation
of the stress-activated protein kinase (SAPK/JNK), but not the
p42 and p44 MAPKs, in transient transfection assays (13, 37,
49, 53). In contrast, oncogenic Ras caused strong activation of
MAPKs and also stimulated SAPK/JNK. Since H-Ras(12V,
37G) and H-Ras(12V, 40C) induced transforming properties
similar to those caused by mutant Rho proteins, we deter-
mined if these two mutants retained the ability to activate
SAPK/JNK. Consistent with our previous observation with
HeLa cells (83), H-Ras(12V) caused a 10-fold activation of
JNK, whereas all three effector domain mutants retained par-
tial ability to activate JNK (2.3- to 3.6-fold activation) in a
transient transfection JNK assay in COS cells (Fig. 5A). We
also observed that NIH 3T3(UNC) cells stably expressing H-
Ras(12V, 37G) and H-Ras(12V, 40C) had approximately 10-
fold higher levels of JNK activities than untransformed cells
and that these activities were equivalent to those seen in H-Ras
(12V)- as well as RhoA(63L)- and Rac1(115I)-transformed
cells (Fig. 5B). These observations, when taken together with
that of the Rho-like transformed phenotype caused by these
two mutants, further suggest the convergence of Rho family
protein-stimulated pathways in mediating, in part, the trans-
forming actions of H-Ras(12V, 37G) and H-Ras(12V, 40C).
Coexpression of the Raf-binding defective mutants of Ras
with activated Raf(340D) caused synergistic enhancement of
their focus-forming activities. Consistent with the proposal
that oncogenic Ras induces transformation by coordinated ac-
tivation of Raf/MEK/MAPK and Rho protein pathways, we
and others have observed that coexpression of activated Raf-1
with activated Rac1 or RhoA caused a dramatic synergistic
enhancement in focus formation (37, 57, 58). Therefore, if the
transforming pathways of H-Ras(12V, 37G) and H-Ras(12V,
40C) converge on the activation of Rho family proteins, we
anticipated that coexpression of activated Raf(340D), which is
a weakly transforming Raf mutant, would also synergistically
enhance the focus-forming activities of Ras effector domain
mutants.
Transfection of weakly activated Raf(340D) alone does not
FIG. 2. H-Ras(12V, 37G) and H-Ras(12V, 40C) exhibit focus-forming activ-
ities which show synergistic cooperation. NIH 3T3(UNC) cells were transfected
with plasmid constructs encoding the indicated Ras mutant proteins, either alone
[10 ng per dish for H-Ras(12V) and 100 ng per dish for each effector domain
mutant] or at a concentration of 50 ng for each effector domain mutant. The
number of transformed foci was quantitated after 14 to 16 days. Focus-forming
activities were normalized to the activities seen with H-Ras(12V) (6.163 103 foci
per mg of transfected DNA). The data shown represent the average of three
dishes and are representative of three independent experiments. FFU, focus-
forming units.
FIG. 3. NIH 3T3(UNC) cells expressing H-Ras(12V, 37G) and H-Ras(12V,
40C) show enhanced growth rates and saturation densities. Sixty-millimeter-
diameter dishes were plated with 105 cells, and the number of cells was deter-
mined on days 1, 3, 5, and 7. The values represent the average of duplicate dishes.
TABLE 2. Transforming properties of Ras effector domain
mutants in NIH 3T3(UNC) cells
Mutant protein Growth inlow seruma
Growth (%) in
soft agarb
No. of sites forming
tumors/no. of sites
inoculatedc
Vector 2 0.0 0/4
H-Ras(12V) 1 7.2 4/4
H-Ras(12V, 35S) 1 5.7 4/4
H-Ras(12V, 37G) 1 2.0 4/4
H-Ras(12V, 40C) 1 2.3 4/4
a Growth in Dulbecco modified Eagle medium supplemented with 1% calf
serum. 2, no colonies formed; 1, colonies formed.
b Percentage of cells plated that formed colonies in 0.35% agar after 14 days.
c Progressive tumor formation (.1 cm in diameter) was detected for animals
inoculated with 105 cells expressing H-Ras(12V), H-Ras(12V, 35S), H-Ras(12,
37G), and H-Ras(12V, 40C) after 10, 12, 20, and 20 days, respectively.
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cause the appearance of transformed foci (37). However, when
we cotransfected expression constructs of Raf(340D) together
with constructs encoding H-Ras(12V, 37G) or H-Ras(12V,
40C), we observed a 7- to 10-fold synergistic enhancement of
their focus-forming activities in NIH 3T3(UNC) cells (Fig. 6A
and B). A similar cooperation was also seen in both NIH 3T3
(CSHL) and NIH 3T3(UNC) transfection assays after the Raf-
binding defective mutants were cotransfected with the Raf-
BXB mutant, which is activated by an N-terminal truncation
and removal of the Ras-binding domain (data not shown). In
addition to enhanced focus-forming activities, we also ob-
served that coexpression of Raf(340D) also restored a Ras-like
appearance to the transformed foci induced by H-Ras(12V,
37G) (Fig. 6C) or H-Ras(12V, 40C) (data not shown). Thus,
coexpression of activated Raf(340D) with either Raf-binding
mutant restored both potent focus-forming activity and the
appearance of transformed foci which are more characteristic
of those seen with H-Ras(12V).
Coexpression of the RhoA(19N) dominant inhibitory mu-
tant blocked the focus-forming activities of H-Ras(12V, 37G)
and H-Ras(12V, 40C). We and others recently showed that
coexpression of dominant negative mutants of RhoA, RhoB,
and Rac1 impaired oncogenic Ras-transforming activity (37,
56, 58). Since the transformed phenotype caused by H-Ras
(12V, 37G) and H-Ras(12V, 40C) was indistinguishable from
those caused by activated Rho proteins, we suspected that
coexpression of the RhoA(19N) dominant inhibitory mutant
would inhibit the focus-forming activities retained by the two
Raf-binding deficient Ras mutants. Because transfection of
H-Ras(12V, 37G) or H-Ras(12V, 40C) alone exhibited poor
focus-forming activity, we determined if coexpression of RhoA
(19N) could inhibit the potent focus-forming activities of these
two mutants after they were coexpressed with Raf(340D). As
can be seen from Fig. 6D, RhoA(19N) greatly impaired the
FIG. 4. H-Ras(12V, 37G) and H-Ras(12V, 40C) cause transformed focus
and cell morphologies, as well as cytoskeletal organization changes, similar to
those caused by transforming RhoA(63L). (A) Representative transformed foci
from cultures transfected with expression plasmids encoding the indicated pro-
teins. (B) The morphologies of NIH 3T3(UNC) cells stably transfected with
plasmid constructs encoding the indicated proteins. Multiple G418-resistant col-
onies (.500) were pooled together to establish each cell line. (C) Actin stress
fibers and focal adhesions were visualized by indirect immunofluorescence with
phalloidin and antivinculin staining, respectively.
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focus-forming activities seen in cultures cotransfected with
Raf(340D) and either H-Ras(12V, 37G) or H-Ras(12V, 40C)
but caused at most a partial inhibition (;20%) of H-Ras(12V,
35S) focus-forming activity. This result is consistent with the
relative inability of RhoA(19N) to block the transforming
Raf22W mutant (37). Thus, these results suggest that the trans-
forming activities of the two Ras mutants defective in Raf
binding require a RhoA or RhoA-related protein function.
H-Ras(12V, 37G) and H-Ras(12V, 40C) cooperate and cause
synergistic enhancement of focus-forming activity. The bind-
ing activities of the H-Ras(12V, 35S), H-Ras(12V, 37G), and
H-Ras(12V, 40C) mutants are all distinct (Table 1), suggesting
that the mutants may each possess distinct effector pathways.
Our previous observation that H-Ras(12V, 35S) and H-Ras
(12V, 37G) can cooperate and show a synergistic enhancement
(8- to 10-fold) of focus-forming activity in NIH 3T3(CSHL)
cells (83) suggested that H-Ras(12V, 37G) retained a Raf-
independent function that contributed to Ras transforming
activity. To determine if H-Ras(12V, 40C) retained a distinct
activity which could cooperate with H-Ras(12V, 35S) or H-Ras
(12V, 37G), we performed cotransfection analyses with these
mutants in NIH 3T3(UNC) cells. Cotransfection of H-Ras
(12V, 40C) with either H-Ras(12V, 35S) or H-Ras(12V, 37G)
caused greatly enhanced focus-forming activities that were
three and fivefold higher, respectively, than the additive activ-
ities of each mutant analyzed alone (Fig. 2). Thus, H-Ras(12V,
40C) provided a complementary activity which cooperated
with the activities of the other two effector domain mutants. It
is unlikely that upregulation of the Raf/MEK/MAPK pathway
is responsible for the synergistic transforming activity seen with
these two Raf-binding defective effector domain mutants, since
their coexpression failed to activate Elk-1 transcription activity
(data not shown). Furthermore, since H-Ras(12V, 37G) and
H-Ras(12V, 40C) are both defective in Raf-1 activation, their
complementary activities suggest the existence of at least two
distinct Raf-independent signaling pathways that mediate Ras
transformation. This enhancement was quantitative, since the
resulting foci retained a Rho-like appearance. Finally, cotrans-
fection of all three effector domain mutants did not result in a
transforming activity that was comparable to oncogenic Ras-
induced transformation. So, collectively, the three mutants to-
gether are probably still deficient in other pathways that con-
tribute to full Ras transformation.
DISCUSSION
We have used two effector domain mutants of oncogenic
Ras [H-Ras(12V, 37G) and H-Ras(12V, 40C)] which are im-
paired in their abilities to bind to Raf-1 in yeast two-hybrid
protein-protein binding analyses and do not activate the Raf/
MAPK pathway in mammalian cells to investigate the contri-
bution of Raf-independent pathways to the oncogenic poten-
tial of Ras. Our results clearly demonstrate that Ras can
promote potent tumorigenic transformation and growth in soft
agar and low serum by stimulation of Raf-independent signal-
ing pathways. Furthermore, we observed that the transformed
phenotype caused by these two Raf-binding defective Ras mu-
tants was distinct from that caused by oncogenic H-Ras(12V)
and, instead, was indistinguishable from the transformed phe-
notype caused by constitutively activated RhoA, RhoB, and
Rac1 proteins. Moreover, the transforming activity of these
two Ras mutants is blocked by dominant negative RhoA. Our
results suggest that the transforming actions of these two Raf-
binding mutants are convergent with and dependent upon Rho
family proteins. We also observed that H-Ras(12V, 37G) and
H-Ras(12V, 40C) cooperate in the induction of foci, indicating
that each mutant retains a distinct Raf-independent activity,
thus raising the possibility that activation of either of two
Raf-independent Ras signaling pathways may lead to tumori-
genic transformation. The identification of multiple numbers
of candidate Ras effectors by yeast two-hybrid library screening
(33, 38, 72, 77, 78), by association with Ras in mammalian cells
(65), or by yeast genetic analyses (10, 27, 77) further supports
the notion that Ras proteins interact with multiple effectors.
The multiplicity of Ras pathways in mammalian cells is echoed
by studies of simple eukaryotes (10, 84).
Since mutated ras sequences are frequently associated with
human carcinomas, Ras-mediated activation of Raf-indepen-
dent pathways may be critical for the tumorigenicity of these
cells. In fact, focus assays with a single fibroblast cell line do
not necessarily reflect the essential roles of Ras in tumors. We
have observed variation in response to Ras mutants even
among strains of NIH 3T3 cells. Although both H-Ras(12V,
37G) and H-Ras(12V, 40C) can cooperate with Raf-1 in NIH
3T3(CSHL), both mutants showed a complete loss of focus-
forming activity in transfected NIH 3T3(CSHL) cells (83).
Furthermore, preliminary results suggest that these mutants
cannot induce tumorigenic transformation of NIH 3T3(CSHL)
cells. These results contrast dramatically with our results with
NIH 3T3(UNC) cells, which can be transformed by both Raf-
dependent and Raf-independent Ras signaling pathways. Yet
other cell lines exhibit different sensitivities. Both H-Ras(12V,
37G) and H-Ras(12V, 40C) caused focus formation of Rat-1
fibroblast and RIE-1 rat intestinal epithelial cells, whereas
Ras-mediated activation of the Raf/MAPK pathway alone is
not sufficient for transformation of this and other epithelial cell
lines (52).
While we cannot rule out the possibility that very low levels
of Raf kinase activity might be responsible for the transforming
activities of H-Ras(12V, 37G) and H-Ras(12V, 40C) mutants,
the transforming properties of these mutants were distinct
from those of H-Ras(12V) and, instead, were indistinguishable
from those of Rho family proteins and their activators. First,
these proteins induced similar types of foci with little change in
cell morphology and actin cytoskeletal organization. Second,
while cells expressing Rho or either H-Ras(12V, 37G) or H-
Ras(12V, 40C) exhibited potent growth-transformed proper-
ties, such as growth in low serum, soft agar, and nude mice,
which were comparable to those seen with H-Ras(12V)-trans-
formed cells, activated Rho and these mutant Ras proteins
only weakly induced foci (37, 56, 58). Third, we recently ob-
served that activated Raf and Rho proteins cooperated and
cause synergistic transforming activity (37, 58), and both Raf-
binding defective mutants of Ras also showed the ability to
cooperate with activated Raf. Furthermore, the recent obser-
vation by Bottorff and colleagues has demonstrated that chi-
FIG. 5. H-Ras(12V, 37G) and H-Ras(12V, 40C) retained the ability to cause
transient or constitutive stimulation of JNK activation. JNK activity was mea-
sured by immunocomplex kinase assays with transiently transfected COS (A) or
stably transfected NIH 3T3(UNC) (B) cells with each pDCR-ras construct.
Numbers represent fold activation relative to vector-transfected cells. The data
shown are representative of three independent assays.
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FIG. 6. Activated Raf(340D) and dominant negative RhoA(19N) caused dif-
ferential abilities to modulate the transforming activities of each effector domain
mutant. (A) NIH 3T3(UNC) cells were transfected with pDCR-ras encoding the
indicated Ras protein, either alone or together with pZIP-rhoA(63L) or pZIP-
raf(340D) plasmids. After 14 days, the dishes were stained with 0.1% crystal
violet to better visualize the transformed foci. (B) Quantitation of the dishes
shown in panel A. The data represent the average of three dishes and are
representative of three independent assays. (C) The appearance of H-Ras(12V,
37G)-induced transformed foci, either alone or with cotransfection of pZIP-
raf(340D) or RhoA(63L). (D) The ability of the RhoA(19N) dominant negative
mutant to inhibit the synergistic focus-forming activity observed with the coex-
pression of Raf(340D) and each Ras mutant was determined. Transformed foci
were quantitated after 14 days. The data represent the average of three dishes
and are representative of three independent assays.
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meras of Ras in which the effector domain is replaced by the
RhoA, Rac1, or CDC42 effector regions can cause foci in a
Rat-2 cell line containing a hyperactivated mutant of MEK1
(8). Since these chimeras are defective in Raf binding and
activation, this observation further supports the model in
which coordinate activation of Raf- and Rho-dependent path-
ways are required for cellular transformation. Fifth, coexpres-
sion of activated Raf converted the transformed morphology
caused by RhoA(63L), as well as those of H-Ras(12V, 37G)
and H-Ras(12V, 40C), to resemble that caused by activated
H-Ras(12V). Sixth, the Raf-binding deficient mutants and ac-
tivated Rho mutants showed the same ranges of host strain
sensitivity: all induced foci and tumorigenicity in NIH 3T3
(UNC) but not in NIH 3T3(CSHL). Finally, both Rho and Ras
mutants caused constitutive upregulation of JNK activity.
Therefore, Ras and Rho most likely have convergent mecha-
nisms of action.
Further experiments indicate that the Raf-independent mech-
anisms are dependent upon Rho or Rho-like proteins. For
example, an interfering form of RhoA blocked focus develop-
ment by Raf(340D) and H-Ras(12V, 37G) or Raf(340D) and
H-Ras(12V, 40C) but did not block focus induction by H-Ras
(12V, 35S) or activated Raf (37). Moreover, Rho protein func-
tion is required for full Ras transforming activity (37, 56, 58),
strongly suggesting that Ras-induced Raf-independent path-
ways may themselves regulate Rho or Rho-mediated activities.
Consistent with this idea, we have observed that yeast S. pombe
ras1 activates a pathway that involves a Rho GEF and Rho
protein (10). Finally, microinjection analyses with Swiss 3T3
cells showed that oncogenic Ras caused membrane ruffling
which was dependent on Rac1 function (62, 63). Further bio-
chemical studies will be needed to rigorously test this particu-
lar hypothesis. Although it is possible that the G-37 or C-40
mutation has converted Ras into mutant proteins that directly
bind Rho effectors, the significant sequence divergence of the
Ras and Rho family protein effector domain sequences argue
against this possibility.
Observations by others that Rho family proteins are regula-
tors of actin cytoskeletal organization (11) have prompted sug-
gestions that Ras-induced morphologic transformation may be
mediated by the activities of Rho proteins. However, cells
transformed by constitutively activated Rho proteins alone do
not exhibit the highly refractile, elongated, and spindle-shaped
morphology which is characteristic of Ras- or Raf-transformed
cells (4, 37, 54, 58, 69). Furthermore, the loss of Raf binding
results in Ras mutants which cause the same limited morpho-
logic transformation seen with activated Rho proteins. There-
fore, the activities which mediate Ras morphologic transfor-
mation more likely represent the action of Ras through the
Raf/MAPK pathway. This possibility is supported by observa-
tions that constitutively activated mutants of MEK1 cause the
same morphologic transformation caused by Ras (3, 45).
In summary, Ras appears to act through multiple pathways.
These pathways can act independently, or synergistically, to
cause cellular transformation. Cell type differences can influ-
ence the sensitivity to transformation by Raf and Raf-inde-
pendent pathways. Whereas the Raf/MAPK pathway alone is
sufficient to cause transformation of NIH 3T3 fibroblasts, Raf-
independent pathways are essential for tumorigenic transfor-
mation of RIE-1 and other epithelial cells (52). Thus, it is im-
portant to resolve what these pathways are and to establish
their contributions to tumorigenicity. The use of Ras effector
domain mutant proteins which show differential impairments
of their abilities to bind to distinct Ras effectors will be impor-
tant in deciphering the complex nature of Ras-mediated signal
transduction and transformation. As demonstrated by this and
our recent study (83), such mutants can be used to define the
importance of a candidate effector target for Ras function. Fur-
thermore, the tumorigenic profile of transgenic animals har-
boring mutants of Ras deficient in specific effector interactions
will determine the contribution of each pathway to tumorigen-
esis. Establishing a role for Raf-independent signaling path-
ways in human carcinogenesis may identify new directions for
antagonizing Ras for cancer treatment.
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